MBMizba Baksh

Mizba Baksh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mizba Baksh has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating tumor DNA for breast cancer: Review of active clinical trials

    by Mizba Baksh, Biraaj Mahajan, Maria M Dufresne, Mira M Shoukry, Samuel Nussbaum, Ali Abbaszadeh-Kasbi, Mohammed Ashary, Jonathan Vandenberg, Emmanuel M Gabriel


  • Open Access

    Advanced Tumor Imaging Approaches in Human Tumors

    by Samuel Nussbaum, Mira Shoukry, Mohammed Ali Ashary, Ali Abbaszadeh Kasbi, Mizba Baksh, Emmanuel Gabriel

    The management of cancer has always relied heavily on the imaging modalities used to detect and monitor it. While many of these modalities have been around for decades, the technology surrounding them is always improving, and much has been discovered in recent years about the nature of tumors because of this. There have been several areas that have aided those discoveries. The use of artificial intelligence has already helped immensely in the quality of images taken but has not yet been widely implemented in clinical settings. Molecular imaging has proven to be useful in diagnosing different types of cancers based on the specificity of the probes/contrast agents used. Intravital imaging has already uncovered new information regarding the heterogeneity of the tumor vasculature. These three areas have provided a lot of useful information for the diagnosis and treatment of cancer, but further research and development in human trials is necessary to allow these techniques to fully utilize the information obtained thus far.


  • Open Access

    Myelomatous ascites and pleural effusion in relapsed multiple myeloma

    by Mizba Baksh, Ke Li, Liuyan Jiang, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan‐Khan, Sikander Ailawadhi, Ricardo D. Parrondo, Muhamad Alhaj Moustafa

    Extramedullary multiple myeloma is seen in advanced and aggressive disease and occurs due to plasma cell infiltration of sites other than the bone marrow. Myelomatous ascites or pleural effusion is seen in less than 1% of cases and can be differentiated from infectious etiologies based on fluid cytology.


  • Open Access

    Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature

    by Mizba Baksh, Liuyan Jiang, Unnati Bhatia, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan‐Khan, Sikander Ailawadhi, Ricardo D. Parrondo

    Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood. We describe a case of an 81‐year‐old woman with LPL who presented with LBL and was successfully treated with chemoimmunotherapy.


  • Open Access

    Myelomatous Ascites and Pleural Effusion in Relapsed Multiple Myeloma

    by Mizba Baksh, Ke Li, Liuyan Jiang, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan-Khan, Sikander Ailawadhi, Ricardo Parrondo, Muhamad Alhaj Moustafa

    Extramedullary multiple myeloma is seen in advanced and aggressive disease and occurs due to plasma cell infiltration of sites other than the bone marrow. Myelomatous ascites or pleural effusion is seen in less than 1 % of cases and can be differentiated from infectious etiologies based on fluid cytology.

  • Open Access

    Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting

    by Thejus Jayakrishnan, Sonikpreet Aulakh, Mizba Baksh, Kianna Nguyen, Meghna Ailawadhi, Ayesha Samreen, Ricardo Parrondo, Taimur Sher, Vivek Roy, Rami Manochakian, et al.

    Background: Concern exists that the clinical trial populations differ from respective cancer populations in terms of their age distribution affecting the generalizability of the results, especially in underrepresented minorities. We hypothesized that the clinical trials that do not report race are likely to suffer from a higher degree of age disparity. Methods: Food and Drug Administration (FDA) drug approvals from July 2007 to June 2019 were reviewed to identify oncology approvals, and trials with age details were selected. The outcomes studied were the weighted mean difference in age between the clinical trial population and real-world population for various cancers, the prevalence of race reporting and association of age and race reporting with each other. Results: Of the 261 trials, race was reported in 223 (85.4%) of the trials, while 38 trials (14.6%) had no mention of race. Race reporting improved minimally over time: 29 (85.3%) in 2007–2010 vs. 49 (80.3%) in 2011–2014 vs. 145 (85.4%) during the period 2015–2019 (p-value = 0.41). Age discrepancy between the clinical trial population and the real-world population was higher for studies that did not report race (mean difference −8.8 years (95% CI −12.6 to −5.0 years)) vs. studies that did report it (mean difference −5.1 years, (95% CI −6.4 to −3.7 years), p-value = 0.04). Conclusion: The study demonstrates that a significant number of clinical trials leading to cancer drug approvals suffer from racial and age disparity when compared to real-world populations, and that the two factors may be interrelated. We recommend continued efforts to recruit diverse populations.


  • Open Access

    Management of Lytic Bone Disease in Lymphoplasmacytic Lymphoma: A Case Report and Review of the Literature

    by Mizba Baksh, Liuyan Jiang, Unnati Bhatia, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan-Khan, Sikander Ailawadhi, Ricardo Parrondo

    Waldenström Macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL and management is poorly understood. We describe a case of an 81-year-old woman with LPL who presented with LBL and was successfully treated with chemoimmunotherapy.

  • Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis

    by Vivek Kumar, Meghna Ailawadhi, Navnita Dutta, Mays Abdulazeez, Chander Shekher Aggarwal, Gerson Quintero, Mizba Baksh, Vivek Roy, Taimur Sher, Victoria Alegria, et al.


  • Open Access

    Aortic Stenosis Patients With Transcatheter Aortic Valve Replacement: Caution Recommended With Renal Failure During Hospitalization

    by Pawandeep Kaur, Temitope Ajibawo, Timiiye Yomi, Neev Patel, Mizba Baksh, Edmond Okotcha, Saurabh Kataria, Rikinkumar S. Patel

    Our study aimed to assess the risk of in-patient mortality due to renal failure and other comorbidities in aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR). We conducted a cross-sectional study using a Nationwide Inpatient Sample (NIS, January 2010 to December 2014) from the United States and included 33,325 patients with a primary diagnosis of AS. Logistic regression was used to evaluate the odds ratio (OR) for in-hospital mortality in AS by comorbidities including renal failure. The prevalence of renal failure in AS patients is 29.2%, and a higher proportion were males (60.1%) and non-white (14.1%). Major loss of function (96.6%) and in-hospital mortality (5.1%) were also proportionally higher in prevalence. Female patients (OR 1.35, 95% CI 1.20-1.51) had higher odds of in-patient mortality in AS patients. Race was a non-significant predictor for mortality risk. Patients with comorbid coagulopathy (OR 2.02, 95% CI 1.79-2.27) and heart failure (OR 1.62, 95% CI 1.39-1.89) have increased mortality in AS inpatients. After controlling confounders, renal failure was significantly associated with increased in-hospital mortality (OR 1.43, 95% CI 1.28-1.61) in AS patients. Renal failure was prevalent in AS patients and was an independent factor that increases the risk of in-hospital mortality by 43%. Due to worse outcomes, more studies are required to evaluate risk-benefit ratio and strategies to improve health-related quality of life in post-TAVR patients with renal failure, and optimally decrease inpatient mortality.


  • Open Access

    Clinical Perspective on 2019 Novel Coronavirus Pneumonia: A Systematic Review of Published Case Reports

    by Rikinkumar S. Patel, Neev Patel, Mizba Baksh, Annam Zaidi, Jaiminkumar Patel

    The ongoing pandemic of 2019 novel coronavirus (2019-nCoV), which originated from Wuhan, China, has led to 68,279 deaths due to 2019-nCoV pneumonia as of May 5, 2020. We conducted a systematic review and included 16 case reports to summarize the transmission and pathology of 2019-nCoV, and clinical presentation, laboratory and imaging findings, and treatment in 2019-nCoV pneumonia. The disease is mild in most people; in some, it may progress to severe pneumonia with acute respiratory distress syndrome (ARDS). Patients with mild illness usually recover at home, with supportive care and isolation in accordance with guidelines. Patients who have moderate to severe pneumonia are usually monitored in the hospital. Although there is no definitive treatment for 2019-nCoV pneumonia so far, some antiviral drugs have shown promising results. The use of lopinavir/ritonavir and remdesivir was associated with significant clinical improvement in severe pneumonia. Nonetheless, we need more randomized clinical trials (RCTs) and treatment guidelines for developing effective management of the 2019-nCoV and improve patient outcomes by reducing mortality in high-risk patients. We also need more clinical trials and management guidelines for the effective management of 2019-nCoV pneumonia.